Literature DB >> 8587353

EndothelinB receptor-mediated contraction of human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin responses in the rat.

K M McCulloch1, M R MacLean.   

Abstract

We investigated the endothelin (ET) receptor subtypes that mediate vasoconstriction in human and rat pulmonary resistance arteries and the effect of pulmonary hypertension on endothelin (ET)-induced contractile responses in rat vessels. In human vessels, sarafotoxin S6c (SXS6c) was more potent than ET-1, but its maximal contractile response was only 20-30% of that to ET-1. Responses to ET-1 were resistant to the ETA antagonist FR 139317, and another, BMS 182874, inhibited responses only to high concentrations of ET-1. In all rat vessels, ET-1, ET-3, and the ETB receptor agonist SXS6c showed the following order of potency: SXS6c = ET-3 > ET-1, and responses to SXS6c were inhibited by the ETB receptor antagonist BQ 788 (1 microM). Maximal responses to ET-1 were greatest in chronic hypoxic (CH) pulmonary-hypertensive rats. In control rats, responses to ET-1 were unaffected by FR 139317 (1 microM) and were potentiated by BMS 182874 (1 microM) and by the mixed ETA/ETB receptor antagonist bosentan (1 microM). A combination of BMS 182874 (10 microM) and the ETB receptor antagonist BQ 788 (1 microM) had no effect on responses to ET-1. In the CH rats, responses to ET-1 were unaffected by FR 139317, BMS 182874, or bosentan. The results suggest the presence of an inhibitory ETA receptor in these vessels that may inhibit ET-1 activation of ETB receptors, and also suggest that the influence of this inhibitory ETA receptor is reduced in CH rat vessels. The results indicate a role for ETB receptors in ET-1-mediated vasoconstriction in both human and rat pulmonary resistance arteries.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587353

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  EndothelinB receptor-mediated contraction in human pulmonary resistance arteries.

Authors:  K M McCulloch; C C Docherty; I Morecroft; M R MacLean
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 2.  Modulators of the vascular endothelin receptor in blood pressure regulation and hypertension.

Authors:  Raouf A Khalil
Journal:  Curr Mol Pharmacol       Date:  2011-11       Impact factor: 3.339

3.  Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure.

Authors:  S J Leslie; J C S Spratt; S P McKee; F E Strachan; D E Newby; D B Northridge; M A Denvir; D J Webb
Journal:  Heart       Date:  2005-07       Impact factor: 5.994

4.  Regional modulation of cyclic nucleotides by endothelin-1 in rat pulmonary arteries: direct activation of G(i)2-protein in the main pulmonary artery.

Authors:  I Mullaney; D M Vaughan; M R MacLean
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

5.  U0126 attenuates cerebral vasoconstriction and improves long-term neurologic outcome after stroke in female rats.

Authors:  Hilda Ahnstedt; Maryam Mostajeran; Frank W Blixt; Karin Warfvinge; Saema Ansar; Diana N Krause; Lars Edvinsson
Journal:  J Cereb Blood Flow Metab       Date:  2014-12-10       Impact factor: 6.200

6.  Endothelin-3-dependent pulmonary vasoconstriction in monocrotaline-induced pulmonary arterial hypertension.

Authors:  Stéphanie Sauvageau; Eric Thorin; Louis Villeneuve; Jocelyn Dupuis
Journal:  Peptides       Date:  2008-08-15       Impact factor: 3.750

Review 7.  Hypoxic pulmonary vasoconstriction.

Authors:  J T Sylvester; Larissa A Shimoda; Philip I Aaronson; Jeremy P T Ward
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 46.500

8.  Extracellular vesicles derived from endothelial cells in hypoxia contribute to pulmonary artery smooth muscle cell proliferation in-vitro and pulmonary hypertension in mice.

Authors:  Tianji Chen; Miranda R Sun; Qiyuan Zhou; Alyssa M Guzman; Ramaswamy Ramchandran; Jiwang Chen; Balaji Ganesh; J Usha Raj
Journal:  Pulm Circ       Date:  2022-01-12       Impact factor: 2.886

9.  Ambrisentan for the treatment of pulmonary arterial hypertension.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

10.  Whole genome sequencing of Ethiopian highlanders reveals conserved hypoxia tolerance genes.

Authors:  Nitin Udpa; Roy Ronen; Dan Zhou; Junbin Liang; Tsering Stobdan; Otto Appenzeller; Ye Yin; Yuanping Du; Lixia Guo; Rui Cao; Yu Wang; Xin Jin; Chen Huang; Wenlong Jia; Dandan Cao; Guangwu Guo; Victoria E Claydon; Roger Hainsworth; Jorge L Gamboa; Mehila Zibenigus; Guta Zenebe; Jin Xue; Siqi Liu; Kelly A Frazer; Yingrui Li; Vineet Bafna; Gabriel G Haddad
Journal:  Genome Biol       Date:  2014-02-20       Impact factor: 13.583

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.